The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial
Open accessAbstract
Summary Background Plasmodium falciparum sporozite (PfSPZ) Vaccine is a metabolically active, non-replicating, whole malaria sporozoite vaccine that has been reported to be safe and protective against P falciparum controlled human malaria infection in malaria-naive individuals. We aimed to assess the safety and protective efficacy of PfSPZ Vaccine against naturally acquired P falciparum in malaria-experienced adults in Mali. Methods After an open-label dose-escalation study in a pilot safety cohort, we did a double-blind, randomised, placebo-controlled trial based in Donéguébougou and surrounding villages in Mali. We recruited 18–35-year-old healthy adults who were randomly assigned (1:1) in a double-blind manner, with stratification by village and block randomisation, to receive either five doses of 2·7 × 105 PfSPZ or normal saline at days 0, 28, 56, 84, and 140 during the dry season (January to July inclusive). Participants and investigators were masked to group assignments, which were unmasked at the final study visit, 6 months after receipt of the last vaccination. Participants received combined artemether and lumefantrine (four tablets, each containing 20 mg artemether and 120 mg lumefantrine, given twice per day over 3 days for a total of six doses) to eliminate P falciparum before the first and last vaccinations. We collected blood smears every 2 weeks and during any illness for 24 weeks after the fifth vaccination. The primary outcome was the safety and tolerability of the vaccine, assessed as local and systemic reactogenicity and adverse events. The sample size was calculated for the exploratory efficacy endpoint of time to first P falciparum infection beginning 28 days after the fifth vaccination. The safety analysis included all participants who received at least one dose of investigational product, whereas the efficacy analyses included only participants who received all five vaccinations. This trial is registered at ClinicalTrials.gov, number . Findings Between Jan 18 and Feb 24, 2014, we enrolled 93 participants into the main study cohort with 46 participants assigned PfSPZ Vaccine and 47 assigned placebo, all of whom were evaluable for safety. We detected no significant differences in local or systemic adverse events or laboratory abnormalities between the PfSPZ Vaccine and placebo groups, and only grade 1 (mild) local or systemic adverse events occurred in both groups. The most common solicited systemic adverse event in the vaccine and placebo groups was headache (three [7%] people in the vaccine group vs four [9%] in the placebo group) followed by fatigue (one [2%] person in the placebo group), fever (one [2%] person in the placebo group), and myalgia (one [2%] person in each group). The exploratory efficacy analysis included 41 participants from the vaccine group and 40 from the placebo group. Of these participants, 37 (93%) from the placebo group and 27 (66%) from the vaccine group developed P falciparum infection. The hazard ratio for vaccine efficacy was 0·517 (95% CI 0·313–0·856) by time-to-infection analysis (log-rank p=0·01), and 0·712 (0·528–0·918) by proportional analysis (p=0·006). Interpretation PfSPZ Vaccine was well tolerated and safe. PfSPZ Vaccine showed significant protection in African adults against P falciparum infection throughout an entire malaria season.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weltgesundheitsorganisation (2005) · Cited by 3,799
Effector and memory T-cell differentiation: implications for vaccine development
Kaech, S. M., Wherry, E. J., & Ahmed, R. (2002) · Nature Reviews Immunology · doi:10.1038/nri778 · Cited by 1,865
Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine
Seder, R. A., Chang, L.-J., Enama, M. E., Zephir, K. L., Sarwar, U. N., Gordon, I. J., Holman, L. A., James, E. R., Billingsley, P. F., Gunasekera, A., et al. (2013) · Science · doi:10.1126/science.1241800 · Cited by 761
Self-citationγ Interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites
Schofield, L., Villaquiran, J., Ferreira, A., Schellekens, H., Nussenzweig, R., & Nussenzweig, V. (1987) · Nature · doi:10.1038/330664a0 · Cited by 713
Hoffman, S. L., Goh, L. M. L., Luke, T. C., Schneider, I., Le, T. P., Doolan, D. L., Sacci, J., de la Vega, P., Dowler, M., Paul, C., et al. (2002) · The Journal of Infectious Diseases · doi:10.1086/339409 · Cited by 688
Self-citationProtection against a Malaria Challenge by Sporozoite Inoculation
Roestenberg, M., McCall, M., Hopman, J., Wiersma, J., Luty, A. J. F., van Gemert, G. J., van de Vegte-Bolmer, M., van Schaijk, B., Teelen, K., Arens, T., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805832 · Cited by 577
Shaping and reshaping CD8+ T-cell memory
Harty, J. T., & Badovinac, V. P. (2008) · Nature Reviews Immunology · doi:10.1038/nri2251 · Cited by 555
Live Attenuated Malaria Vaccine Designed to Protect Through Hepatic CD8 + T Cell Immunity
Epstein, J. E., Tewari, K., Lyke, K. E., Sim, B. K. L., Billingsley, P. F., Laurens, M. B., Gunasekera, A., Chakravarty, S., James, E. R., Sedegah, M., et al. (2011) · Science · doi:10.1126/science.1211548 · Cited by 533
Self-citationBojang, K. A., Milligan, P. J., Pinder, M., Vigneron, L., Alloueche, A., Kester, K. E., Ballou, W. R., Conway, D. J., Reece, W. H., Gothard, P., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06957-4 · Cited by 528
Immunization of man against sporozite-induced falciparum malaria
CLYDE, D. F., MOST, H., McCARTHY, V. C., & VANDERBERG, J. P. (1973) · The American Journal of the Medical Sciences · doi:10.1097/00000441-197309000-00002 · Cited by 524
Cited by
Ashley, E. A., Pyae Phyo, A., & Woodrow, C. J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30324-6 · Cited by 553
Sterile protection against human malaria by chemoattenuated PfSPZ vaccine
Mordmüller, B., Surat, G., Lagler, H., Chakravarty, S., Ishizuka, A. S., Lalremruata, A., Gmeiner, M., Campo, J. J., Esen, M., Ruben, A. J., et al. (2017) · Nature · doi:10.1038/nature21060 · Cited by 403
Self-citationMalaria Vaccines: Recent Advances and New Horizons
Draper, S. J., Sack, B. K., King, C. R., Nielsen, C. M., Rayner, J. C., Higgins, M. K., Long, C. A., & Seder, R. A. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.06.008 · Cited by 331
Malaria vaccines since 2000: progress, priorities, products
Duffy, P. E., & Patrick Gorres, J. (2020) · npj Vaccines · doi:10.1038/s41541-020-0196-3 · Cited by 266
Self-citationT cell-mediated immunity to malaria
Kurup, S. P., Butler, N. S., & Harty, J. T. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0158-z · Cited by 242
Metadata
- Authors
- Sissoko, M. S., Healy, S. A., Katile, A., Omaswa, F., Zaidi, I., Gabriel, E. E., Kamate, B., Samake, Y., Guindo, M. A., Dolo, A., Niangaly, A., Niaré, K., Zeguime, A., Sissoko, K., Diallo, H., Thera, I., Ding, K., Fay, M. P., O'Connell, E. M., Nutman, T. B., Wong-Madden, S., Murshedkar, T., Ruben, A. J., Li, M., Abebe, Y., Manoj, A., Gunasekera, A., Chakravarty, S., Sim, B. K. L., Billingsley, P. F., James, E. R., Walther, M., Richie, T. L., Hoffman, S. L., Doumbo, O., & Duffy, P. E.
- Venue
- The Lancet Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2017-05
- Volume
- 17
- Issue
- 5
- Pages
- 498-509
- ISSN
- 1473-3099 (ISSN-L)
- OpenAlex
- W2587907012
- Cited by
- 309
- References
- 27
- FWCI
- 32.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. https://app.cochat.ai/papers/10.1016/s1473-3099(17)30104-4
- The paper
- Sissoko, M. S., Healy, S. A., Katile, A., Omaswa, F., Zaidi, I., Gabriel, E. E., Kamate, B., Samake, Y., Guindo, M. A., Dolo, A., Niangaly, A., Niaré, K., Zeguime, A., Sissoko, K., Diallo, H., Thera, I., Ding, K., Fay, M. P., O'Connell, E. M., . . . Duffy, P. E. (2017). Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(17)30104-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.